Pharming Group (OTCMKTS:PHGUF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

PHGUF stock opened at $1.20 on Tuesday. Pharming Group has a twelve month low of $0.76 and a twelve month high of $1.96. The stock has a market cap of $723.77 million, a P/E ratio of -6.67 and a beta of 2.92. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.19 and a current ratio of 1.51.

Pharming Group (OTCMKTS:PHGUF) last released its earnings results on Thursday, July 26th. The biotechnology company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. Pharming Group had a negative return on equity of 357.23% and a negative net margin of 36.30%. The business had revenue of $35.77 million for the quarter, compared to the consensus estimate of $38.86 million. sell-side analysts predict that Pharming Group will post 0.02 earnings per share for the current fiscal year.

About Pharming Group

Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein.

Recommended Story: What is a Stop Order?

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.